Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies. This decision aligns Carisma's efforts with next-gene
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5th at 9:35 am ET.
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engineered macrophages for treating liver fibrosis at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. These results underscore the pre-clinical efficacy of Carisma's engineered macrophages in multiple liver fibrosis models and offer
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully crea
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2024, and highlighted recent business updates.
Yahoo
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data will be presented in a p
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 47.98% | $290.25M | 0% |
CPRJ | 41.48% | $48.46M | 0.69% |
PTH | 35.00% | $110.42M | 0.6% |
ARKG | 34.93% | $977.87M | 0.75% |
IWC | 34.07% | $810.14M | 0.6% |
XBI | 33.59% | $5.33B | 0.35% |
PRNT | 33.45% | $74.53M | 0.66% |
PINK | 33.08% | $141.43M | 0.5% |
XPH | 31.48% | $156.75M | 0.35% |
IWO | 30.89% | $10.88B | 0.24% |
GNOM | 30.87% | $53.29M | 0.5% |
VTWO | 30.84% | $10.91B | 0.07% |
IWM | 30.69% | $64.21B | 0.19% |
IBB | 30.67% | $5.92B | 0.45% |
KJUL | 30.43% | $155.38M | 0.79% |
SCHA | 30.03% | $15.95B | 0.04% |
KOMP | 29.85% | $1.95B | 0.2% |
QAI | 29.84% | $689.89M | 0.91% |
ISCG | 29.81% | $654.50M | 0.06% |
IWN | 29.69% | $10.97B | 0.24% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -20.88% | $195.31M | 0.85% |
TAIL | -19.56% | $86.92M | 0.59% |
ULST | -17.25% | $587.03M | 0.2% |
DBA | -16.88% | $822.16M | 0.93% |
SPSK | -15.64% | $296.56M | 0.5% |
BTAL | -13.89% | $404.97M | 1.43% |
TFLO | -13.84% | $6.78B | 0.15% |
UUP | -12.23% | $327.80M | 0.77% |
JMST | -11.22% | $3.55B | 0.18% |
USDU | -11.20% | $213.46M | 0.5% |
TPMN | -9.23% | $33.51M | 0.65% |
CORN | -9.10% | $51.34M | 0.2% |
IBD | -8.91% | $381.57M | 0.44% |
WEAT | -8.77% | $113.78M | 0.28% |
CARY | -8.76% | $347.36M | 0.8% |
STPZ | -8.75% | $443.63M | 0.2% |
CLOI | -8.68% | $1.02B | 0.4% |
TAXF | -8.18% | $515.52M | 0.29% |
SOYB | -8.02% | $25.81M | 0.22% |
CGMU | -7.89% | $2.96B | 0.27% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LPRO | 35.94% | $329.41M | -53.69% | 0.00% |
CLRB | 32.14% | $14.53M | -91.96% | 0.00% |
CMBM | 32.09% | $19.93M | -83.59% | 0.00% |
LUV | 31.17% | $19.90B | +15.08% | 2.19% |
BEAM | 30.87% | $1.95B | -40.20% | 0.00% |
LILA | 29.64% | $1.25B | -9.57% | 0.00% |
IDYA | 29.51% | $1.43B | -61.48% | 0.00% |
OVID | 29.09% | $22.17M | -89.91% | 0.00% |
CRSP | 28.76% | $2.92B | -50.09% | 0.00% |
FATE | 28.75% | $90.54M | -88.84% | 0.00% |
LILAK | 28.54% | $1.22B | -11.66% | 0.00% |
SYRE | 28.48% | $972.25M | -56.39% | 0.00% |
IMNM | 28.37% | $585.18M | -69.56% | 0.00% |
RXRX | 27.99% | $2.13B | -43.54% | 0.00% |
BLFS | 27.96% | $1.07B | +27.60% | 0.00% |
NNOX | 27.82% | $292.21M | -51.65% | 0.00% |
RYTM | 27.77% | $3.35B | +24.11% | 0.00% |
GYRE | 27.72% | $666.48M | -51.29% | 0.00% |
RDW | 27.65% | $626.50M | +89.70% | 0.00% |
VRA | 27.65% | $62.38M | -66.42% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FXY | -<0.01% | $546.19M | 0.4% |
JCPB | -0.01% | $6.08B | 0.38% |
XHLF | 0.03% | $1.06B | 0.03% |
AFIF | -0.06% | $135.76M | 1.11% |
LGOV | -0.06% | $658.58M | 0.67% |
FIXD | -0.10% | $4.05B | 0.65% |
USL | -0.11% | $46.60M | 0.85% |
AGZD | 0.12% | $136.29M | 0.23% |
EAGG | -0.13% | $3.77B | 0.1% |
DBC | -0.14% | $1.32B | 0.87% |
GCOR | 0.14% | $356.03M | 0.08% |
PHDG | -0.15% | $114.12M | 0.39% |
AVIG | -0.15% | $1.09B | 0.15% |
SLQD | -0.16% | $2.23B | 0.06% |
FLCB | 0.18% | $2.42B | 0.15% |
IBDS | -0.18% | $2.96B | 0.1% |
CANE | -0.20% | $11.05M | 0.29% |
TBLL | 0.22% | $2.07B | 0.08% |
DFCF | 0.25% | $6.61B | 0.17% |
IBDZ | -0.26% | $294.40M | 0.1% |
Current Value
$0.301 Year Return
Current Value
$0.301 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AHCO | 0.01% | $1.46B | -3.21% | 0.00% |
DKS | -0.03% | $16.42B | -9.15% | 2.24% |
IMNN | 0.08% | $15.35M | -45.60% | 0.00% |
PBA | -0.08% | $23.24B | +12.95% | 4.96% |
SWI | -0.08% | $3.19B | +57.39% | 0.00% |
FLYW | 0.12% | $1.17B | -59.81% | 0.00% |
EW | -0.12% | $42.46B | -23.10% | 0.00% |
QURE | -0.13% | $573.22M | +103.45% | 0.00% |
NOC | 0.14% | $74.12B | +8.63% | 1.60% |
KLG | 0.18% | $1.72B | +0.71% | 3.23% |
BBDO | -0.18% | $11.04B | -12.44% | 1.76% |
ADM | -0.20% | $23.05B | -23.00% | 4.19% |
MVO | 0.20% | $62.10M | -50.68% | 23.99% |
MRK | 0.21% | $226.74B | -31.48% | 3.52% |
MODV | 0.21% | $18.86M | -94.16% | 0.00% |
KHC | 0.28% | $36.36B | -17.89% | 5.22% |
BF.A | -0.30% | $15.82B | -36.08% | 2.64% |
GOOG | 0.34% | $1.90T | -0.17% | 0.51% |
ELF | -0.34% | $3.54B | -67.29% | 0.00% |
EL | -0.35% | $23.74B | -56.59% | 3.02% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MSDL | -14.06% | $1.77B | -6.49% | 10.02% |
LITB | -10.61% | $36.77M | -56.14% | 0.00% |
CBOE | -10.04% | $23.69B | +24.42% | 1.08% |
PDCO | -9.40% | $2.76B | +15.40% | 2.50% |
MCK | -8.21% | $84.34B | +25.44% | 0.41% |
TCTM | -7.93% | $3.39M | -83.19% | 0.00% |
STNG | -7.65% | $1.88B | -48.34% | 4.25% |
ACCD | -7.44% | $572.31M | -31.10% | 0.00% |
CYCN | -7.21% | $6.78M | -18.57% | 0.00% |
LFVN | -7.19% | $183.00M | +128.17% | 1.05% |
K | -6.96% | $28.48B | +44.57% | 2.75% |
CMG | -6.68% | $68.05B | -12.74% | 0.00% |
REYN | -6.59% | $5.01B | -17.55% | 3.85% |
NKE | -6.42% | $93.90B | -31.42% | 2.41% |
PG | -6.23% | $399.61B | +6.13% | 2.36% |
UTZ | -6.12% | $1.21B | -24.20% | 1.69% |
DEO | -6.03% | $58.22B | -29.11% | 3.94% |
MNST | -5.98% | $56.95B | +1.35% | 0.00% |
STG | -5.24% | $28.45M | -43.90% | 0.00% |
VHC | -5.01% | $31.32M | +18.43% | 0.00% |